Brexanolone for the treatment of patients with postpartum depression.

Clicks: 217
ID: 57814
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso (brexanolone) for intravenous use for the treatment of postpartum depression (PPD) in adult women. The decision was based on three recent clinical trials following an FDA priority review and breakthrough therapy designation. Brexanolone is now available through a restricted process called the Zulresso Risk Evaluation and Mitigation Strategy Program that requires the drug to be administered by a healthcare provider in a certified healthcare facility. Brexanolone represents an important new treatment option to address treatment-resistant depressive symptoms. In this article, we discuss the current critical need for PPD treatments, the mechanisms of brexanolone action, and the efficacy and drug safety studies that led to FDA approval. Additionally, we discuss some limitations of the current formulation, specific populations of women that might benefit from this treatment, and how new drugs on the horizon may increase the ability to treat PPD in a variety of patient populations.
Reference Key
morrison2019brexanolonedrugs Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Morrison, K E;Cole, A B;Thompson, S M;Bale, T L;
Journal drugs of today (barcelona, spain : 1998)
Year 2019
DOI
10.1358/dot.2019.55.9.3040864
URL
Keywords
postpartum depression antidepressants brexanolone gaba(a) receptor modulators neurosteroids zulresso

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.